MLTX Valuation

MoonLake Immunotherapeutics

Add to Watchlist

Advanced Chart

55.070

+0.04(0.073%)1D

Overview
Forecast
Valuation
Earnings

MLTX Relative Valuation

MLTX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, MLTX is overvalued; if below, it's undervalued.

Historical Valuation

MoonLake Immunotherapeutics (MLTX) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -21.54. The fair price of MoonLake Immunotherapeutics (MLTX) is between to according to relative valuation methord.

Relative Value

Fair Zone

Current Price：55.07

Fair

Trailing

Forward

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

8.58

P/B

Median3y

8.10

Median5y

6.91

-4.01

FCF Yield

Median3y

-5.54

Median5y

-6.95

Competitors Valuation Multiple

The average P/S ratio for MLTX's competitors is 5.88, providing a benchmark for relative valuation. MoonLake Immunotherapeutics Corp (MLTX) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

MLTX.O

MoonLake Immunotherapeutics

Loss

Average P/S: 5.88

3.54B